Researchers and companies disclosed a scalable manufacturing pathway for CAR-expressing induced natural killer (CAR-iNK) cells, aiming to lower cost and increase supply for off-the-shelf cell therapies. The approach focuses on streamlined expansion, consistent transduction, and process controls designed for industrial bioprocessing environments. The method targets limitations of autologous CAR-T production by enabling larger batch sizes and reduced per-dose variability. If translated to GMP settings, the process could accelerate clinical testing and commercialization of CAR-NK therapies across hematologic and solid tumor indications, where NK platforms promise reduced toxicity and simpler logistics.